Cardiac risk: Not so simple

Journal of Infectious Diseases

Volumn 201, Issue 3, 2010, Pages 315-317

  Aberg, Judith A ^a,b   Ribaudo, Heather ^c  

^a BELLEVUE HOSPITAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR;

ANTIVIRAL THERAPY; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SEX RATIO; UNSPECIFIED SIDE EFFECT; CORONARY ARTERY DISEASE; EDITORIAL; RESEARCH;

ANTI-HIV AGENTS; CORONARY DISEASE; HIV INFECTIONS; HUMANS; RESEARCH; RISK FACTORS;

EID: 75649110460     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/649898     Document Type: Note

References (16)

1. Aberg J. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr 2009; 50:54-64.
2. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952. (Pubitemid 39208455)
3. DAD Study Group, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735. (Pubitemid 46658704)
4. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Infect Dis 2010;201:318-330 (in this issue).
5. Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD study groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17-F24.
6. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay C, GRUCHUM Research Center (Groupe de Recherche de l'UHRESS du Centre Hospitalier Universitaire de Montréal). Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec's public health insurance database (QPHID). In: Program and abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Geneva, Switzerland: International AIDS Society, 2009. Abstract TUPEB175.
7. Lang S, Mary-Krause M, Cotte L, et al. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Conference on Retroviruses and Opportunistic Infections, 2009. Abstract 43 LB.
8. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009;49:1591-1601.
9. Bedimo R, Westfall A, Drechsler H, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. In: Program and abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Geneva, Switzerland: International AIDS Society, 2009. Abstract MOAB202.
10. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy no increased risk across 52 Glaxo-SmithKline- sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20-28.
11. McComsey G, Smith K, Patel P, et al. Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/lamivudine or tenofovir/emtricitabine: the HEAT study. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Conference on Retroviruses and Opportunistic Infections, 2009. Abstract 732.
12. Benson C, Ribaudo H, Zheng E, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Conference on Retroviruses and Opportunistic Infections, 2009. Abstract 721.
13. Hughes MD, Williams PL. Challenges in using observational studies to evaluate adverse effects of treatment. N Engl J Med 2007; 356: 1705-1707. (Pubitemid 46658701)
14. Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366: 378-384. (Pubitemid 41073955)
15. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570. (Pubitemid 30660035)
16. Hernan MA. A definition of causal effect for epidemiological research. J Epidemiol Community Health 2004;58:265-271.